Clinical trials: insulin glargine
Type 2 Diabetes
Levemir-Body Composition and Energy Metabolism
The objectives is to compare the changes in body composition (primary objective), diabetes parameters, energy expenditure and energy intake between Insulin detemir (Levemir® - Novolin® 4 pen) and insulin glargine (Lantus® …
- Trial name
- NCT00862875
- Testing
- Detemir or Glargine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Diabetes Mellitus, Type 2
Insulin Glargine "All to Target" Trial
The primary objectives were: To demonstrate the superiority of Lantus plus stepwise addition of mealtime Apidra® (Lantus/Apidra-3) versus twice-daily Premixed insulin based on the proportion of patients achieving target glycemic…
- Trial name
- NCT00384085
- Testing
- Insulin Glulisine, Insulin Glargine, Premixed Insulin
- Where
- United States
- Volunteers
- 588 people
- Sponsor
- Sanofi
Diabetes Mellitus
Satisfaction of Treatment Among Elderly Patients With Insulin Therapy
Several studies have shown that high blood sugar (glucose) levels are associated with diseases caused by diabetes. Controlling the glucose may prevent these complications.
- Trial name
- NCT01240200
- Testing
- Glargine, glargine via insulin pen
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Emory University
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the…
- Trial name
- LEAD-5 (NCT00331851)
- Testing
- liraglutide, insulin glargine, metformin
- Where
- 116 sites in Argentina, Austria and 16 more
- Volunteers
- 584 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.
- Trial name
- NCT06370715
- Testing
- Insulin Lispro-aabc, Insulin Glargine
- Where
- 12 sites in India
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with insulin glargine in patients with type 2 diabetes…
- Trial name
- BOOST™ (NCT01045447)
- Testing
- insulin degludec/insulin aspart, insulin glargine
- Where
- 65 sites in United States, Croatia and 7 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Management of Type 2 Diabetes After Gastric Bypass Surgery
Gastric bypass surgery has been proposed as an effective treatment strategy for type 2 diabetes mellitus (T2DM), but thus far algorithms for the management of T2DM immediately after surgery have not been established.
- Trial name
- NCT01213563
- Testing
- Actrapid insulin+Gloucose, Actrapid insulin
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Imperial College London
Gestational Diabetes Mellitus, Pregnancy, High Risk
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational…
- Trial name
- DECIDE (NCT06445946)
- Testing
- Metformin, Insulin
- Where
- 26 sites in United States
- Volunteers
- 1,572 people
- Sponsor
- Ohio State University
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp)…
- Trial name
- BEGIN™ (NCT00972283)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 136 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,006 people
- Sponsor
- Novo Nordisk A/S
Type2diabetes
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
In this study, we aim to explore the beneficial effect of early short-term (two weeks), self-titrated, basal-only insulin therapy on the degree of glycemic control over 1-year follow through a prospective cohort.
- Trial name
- NCT06107153
- Testing
- Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Pioglitazone 30mg
- Where
- Iraq
- Volunteers
- 243 people
- Sponsor
- University of Basrah
Diabetes Mellitus, Type 2
Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
Primary Objective: The primary objective is to describe the effect of insulin glargine (U300) in type 2 diabetes mellitus (T2DM) patients uncontrolled with their current basal insulin therapy and eligible for basal switching…
- Trial name
- Transition II (NCT02967237)
- Testing
- insulin glargine (U300)
- Where
- 85 sites in France
- Volunteers
- 136 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Insulin Glargine Versus Twice-Daily NPH
To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.
- Trial name
- NCT00687453
- Testing
- Insulin glargine at bedtime instead of NPH, NPH twice-daily
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Charles Drew University of Medicine and Science
Type 2 Diabetes
Comparing the Effects of Insulin Glargine on Blood Glucose Between Needle-free Jet Injection and Insulin Pen
To comparing the blood sugar improvement and patient sensibility of insulin glargine injected with needle-free jet injector and conventional insulin pen
- Trial name
- NCT04074603
- Testing
- The needle-free jet injector, Conventional insulin pen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jian-hua Ma
Type 1 Diabetes
Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls
Intensive control of Type 1 Diabetes is critical in prevention of long term complications. Unfortunately, there is a three-fold increase in hypoglycemia with intensive control.
- Trial name
- NCT00927524
- Testing
- Insulin glulisine, Insulin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood sugar lowering effect of biphasic insulin aspart 30 once daily compared to insulin glargine once daily both in combination with metformin…
- Trial name
- EasyMix (NCT01123980)
- Testing
- biphasic insulin aspart 30, metformin, glimepiride
- Where
- 34 sites in China, Japan
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Hyperglycemia, Leukemia
Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia
RATIONALE: Controlling blood sugar levels may be effective in preventing infections in patients receiving chemotherapy for acute myeloid leukemia or acute lymphoblastic leukemia.
- Trial name
- NCT00943709
- Testing
- insulin glargine recombinant, therapeutic insulin
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Type 2 Diabetes
The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes
Gastric emptying is now recognized as a major determinant of the blood glucose response to carbohydrate in both health and type 2 diabetes (T2D).
- Trial name
- NCT05284344
- Testing
- Anti-Diabetics
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- University of Adelaide
Diabetes Mellitus, Type 2
Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
The primary objective is to demonstrate the non-inferiority at six months of a basal plus one insulin regimen (Lantus plus one injection of Apidra) compared with a biphasic insulin regimen (NovoMix 30) at controlling glycosylated…
- Trial name
- LanScape (NCT00965549)
- Testing
- INSULIN GLARGINE (HOE901), Insulin aspart, Insulin Glulisine
- Where
- 74 sites in Australia, United Kingdom
- Volunteers
- 463 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
This trial was conducted in Europe and North America. The aim of this clinical trial was to compare NN1250 (insulin degludec (IDeg)), a soluble insulin basal analogue (SIBA), with insulin glargine (IGlar), as add-on to subject's…
- Trial name
- BEGIN™ (NCT01076647)
- Testing
- insulin degludec, insulin glargine
- Where
- 105 sites in United States, Bulgaria and 5 more
- Volunteers
- 467 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler
This is an open-label, randomized, forced-titration clinical trial evaluating the efficacy and safety of Technosphere Insulin (TI) Inhalation Powder in combination with insulin glargine versus insulin aspart in combination with…
- Trial name
- NCT01196104
- Testing
- Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine
- Where
- 29 sites in United States
- Volunteers
- 39 people
- Sponsor
- Mannkind Corporation